Eurofins Scientific SE's quarterly market cap
increased
from Dec. 2024 ($9,798 Mil) to Jun. 2025 ($12,763 Mil) and
increased
from Jun. 2025 ($12,763 Mil) to Dec. 2025 ($12,951 Mil).
Eurofins Scientific SE's annual market cap
declined
from Dec. 2023 ($12,349 Mil) to Dec. 2024 ($9,798 Mil) but then
increased
from Dec. 2024 ($9,798 Mil) to Dec. 2025 ($12,951 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Eurofins Scientific SE's Enterprise Value for Today is $17,448 Mil.
Eurofins Scientific SE (OTCPK:ERFSF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Eurofins Scientific SE's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's Market Cap distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Eurofins Scientific SE's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eurofins Scientific SE (ERFSF) has a Market Cap of $13,249 Mil as of Jun. 24, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Eurofins Scientific SE and its competitors. According to the industry distribution chart, Eurofins Scientific SE ranks #16 out of 219 companies in the Medical Diagnostics & Research industry, placing it in the top 7.3%.
Is Eurofins Scientific SE's Market Cap too high?
Eurofins Scientific SE's current Market Cap is $13,249 Mil. The Medical Diagnostics & Research industry median Market Cap is 56.68. Eurofins Scientific SE's value of $13,249 Mil is 23276.7% above this industry median. Based on the distribution chart, Eurofins Scientific SE ranks #16 out of 219 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Eurofins Scientific SE has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's Market Cap compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #16 out of 219 companies for Market Cap. This places Eurofins Scientific SE in the top 7% of its industry — outperforming the majority of peers. The industry median Market Cap is 56.68. Eurofins Scientific SE's value of $13,249 Mil is 23276.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 56.68, based on 219 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current Market Cap of $13,249 Mil is 23276.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Eurofins Scientific SE and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 56.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current Market Cap is $13,249 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $76.00, compared to a current price of $76.03 — trading 0% above its estimated fair value. The current Market Cap is $13,249 Mil and 23276.7% above the Medical Diagnostics & Research industry median of 56.68. Eurofins Scientific SE's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current Market Cap is $13,249 Mil as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of $76.03 is trading 0% above its estimated GF Value™ of $76.00.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for ERFSF:
Market Cap: $13,249 Mil
GF Value™: $76.00 vs. price of $76.03 (0% above fair value)
Industry Position: 23276.7% above the Medical Diagnostics & Research median (#16 of 219)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
81GF Score
Get the complete analysis for ERFSF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
